GeoVax Q2 net loss $4.4M ($0.97/share); advancing GEO-MVA pivotal study planned Q4 2026

GeoVax Labs, Inc.

Net loss for Q2 2026 was $4.4M ($0.97 per share) vs $5.4M ($8.74 per share) in Q2 2025.
No revenue in Q2 2026 after BARDA contract termination; Q2 2025 had $852K government contract revenue.
Cash $3.1M at June 30, 2026, unchanged from Dec 31, 2025.
Discontinued GEO-CM04S1 COVID-19 vaccine development due to market contraction; no safety concerns.
Planning to initiate pivotal GEO-MVA immunobridging study in Q4 2026 under EMA expedited pathway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.